# A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors

> **NCT05649761** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 61 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** QL1604 injection

## Key facts

- **NCT ID:** NCT05649761
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-29
- **Primary completion:** 2020-07-10
- **Final completion:** 2023-01-23
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05649761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05649761, "A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05649761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*